AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03158922 — intervention group
Intervention type: OTHER
Intervention: Prostate cancer screening
Description: Prostate cancer screening in the form of PSA testing will be offered to all men who have a benign biopsy result for five years in order to track development of cancer in the future.
Study NCT03158922 — intervention group
Intervention type: PROCEDURE
Intervention: Prostate biopsy
Description: Prostate biopsy will be offered to men identified within the top 10% genetic risk score profile.
Study NCT05869201 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine [inactivated]
Description: Solution for intramuscular injection, 0.5 ml (1 dose) Vaccination with a single dose vaccine
Study NCT05869201 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine [inactivated]
Description: Solution for intramuscular injection, 0.5 ml (1 dose) Vaccination with a single dose vaccine
Study NCT03996902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored intervention
Description: Brief motivational smoking intervention tailored to address smoking in the context of pain. Included a novel pain-smoking psycho education component, personalized feedback component, and elicitation of participant's pain-related goals to develop discrepancy between continued smoking and desired pain outcomes.
Study NCT03996902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ask-Advise-Refer
Description: The Ask-Advise-Refer intervention is commonly used in standard clinical practice.
Study NCT04495569 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant anti-rabies human monoclonal antibody injection (SYN023)
Description: The finished product of SYN023 is a mixture of two anti-rabies human monoclonal antibodies, CTB011 and CTB012 by equal quantity, containing 3.0 mg/mL active ingredients in both.
Study NCT04495569 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies Vaccine
Description: The Chinese licensed Vero Cell Freeze-dried Rabies Vaccine was injected to Cohort B as per the vaccination precedure on Days 1, 4, 8, 15, 28 respectively.
Study NCT01364376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1; Oxaliplatin; 5-Fu; Leucovorin Calcium
Description: FOLFOX:~oxaliplatin 130mg/m2 on day 1, CF 400mg/m2 on day 1, 5-Fu 400mg/m2 on day 1; 5-FU 2400 mg/m2 46hr civ regimen repeated every 3 weeks Pre-operative chemotherapy: 2-4 cycles and peri-operative chemotherapy consist of 6 cycles~SOX:~oxaliplatin 130mg/m2 on day 1, S-1 for 14 days regimen repeated every 3 weeks Pre-chemotherapy: 2-4 cycles, totally 6 cycles of perioperative chemotherapy
Study NCT01364376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1; Oxaliplatin; 5-Fu; Leucovorin Calcium
Description: FOLFOX:~oxaliplatin 130mg/m2 on day 1, CF 400mg/m2 on day 1, 5-Fu 400mg/m2 on day 1; 5-FU 2400 mg/m2 46hr civ regimen repeated every 3 weeks Pre-operative chemotherapy: 2-4 cycles and peri-operative chemotherapy consist of 6 cycles~SOX:~oxaliplatin 130mg/m2 on day 1, S-1 for 14 days regimen repeated every 3 weeks Pre-chemotherapy: 2-4 cycles, totally 6 cycles of perioperative chemotherapy
Study NCT03311204 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BlephEx
Description: BlephEx is an instrument that contains a hand piece used to spin a medical grade micro-sponge along the edge of eyelids and lashes that helps in removing scurf and debris from eyelids and helps in exfoliating the lids. A new micro-sponge will be used for every subject to avoid cross-contamination. This procedure lasts for 6-8 mins.
Study NCT03311204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lid Hygenix
Description: Foam-based hypoallergenic cleanser used to clean eyelid margins is used as a control intervention for the study.
Study NCT00599365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacy care arm
Description: * The pharmacist will take all your medication bottles, and give you medication boxes filled with your medications in the order you should take them in.~* You will need to give a complete list of medications to the pharmacist.~* You will need to describe how you take these medications.~* The pharmacist will teach you about the medications. This includes side effects, drug interactions, and directions.~* The pharmacist will give you a medication schedule, and other papers about your medications.
Study NCT02700828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: 4 \* 0,5 mg/kg /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
Study NCT02700828 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 \* 2 ml isotonic sodium chloride solution /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
Study NCT01345669 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily
Study NCT01345669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Once daily
Study NCT01750723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: 1 g diluted in 10 ml saline, i.v. bolus injection.
Study NCT04478448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flupirava
Description: 1 tablet contains 200 mg Favipiravir
Study NCT04478448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avigan
Description: 1 tablet contains 200 mg Favipiravir
Study NCT00516165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Oral pills taken daily in a 42-day cycle (6 weeks). Cycles will be repeated every 42 days
Study NCT04078581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire and fecal sample collection
Description: Questionnaire and fecal sample collection in order to select donors for FMT.
Study NCT01665274 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: D2 resection
Description: D2 resection
Study NCT01665274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D2 resection
Description: D2 resection
Study NCT00764621 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primovist MRI
Description: Contrast-enhanced MRI with an i.v. application of Primovist in the approved dosage
Study NCT04168437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health-Related Quality of Life Report
Description: Two page report and interpretation guide based on SPADE cluster scores
Study NCT02813733 — intervention group
Intervention type: PROCEDURE
Intervention: Thyroid surgery
Description: Thyroidectomies performed by all surgeons in 5 academic hospitals in France.
Study NCT01288729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sure-T Steel Infusion Set Catheter
Description: Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
Study NCT01288729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quick-Set Teflon Catheter
Description: Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
Study NCT01263652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac hydroxyethylpyrrolidine
Description: IM/PO
Study NCT01263652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: orphenadrine
Description: IM/PO orphenadrine
Study NCT01263652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: IM/PO tramadol
Study NCT01263652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyrone
Description: PO/IM Dipyrone
Study NCT01871870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas Control Software
Description: This master controller software is used in conjunction with two subcutaneous continuous glucose monitoring systems and two Omnipod pumps, one for administering aspart insulin (NovoLog) and one for administering glucagon (GlucaGen), to control blood glucose levels. The insulin and glucagon infusion rates are determined by an outpatient automated version of the Adaptive Proportional Derivative (APD) insulin and glucagon control algorithm programmed into a smart phone.
Study NCT03550989 — intervention group
Intervention type: OTHER
Intervention: Non-Exposure Event
Description: Non-Exposure event of 4h duration for the individual participants, where no use of any tobacco or nicotine-containing product is allowed, designed to establish background measurements in the absence of exposure to IQOS.
Study NCT03550989 — intervention group
Intervention type: OTHER
Intervention: Exposure Event
Description: Exposure Event designed to measure urinary BoExp to selected HPHCs representative of ETS in all participant groups, with up to 5h of exposure to IQOS tobacco environmental aerosol for non-smokers, cigarette smokers (not using any tobacco or nicotine-containing product, including cigarettes), and IQOS passive users (not using IQOS). Additionally, this event includes up to 8h of exposure for IQOS active users (using IQOS).
Study NCT02862743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patients with metastatic melanoma
Description: Blood sample to realize molecular characterization of melanoma
Study NCT01772290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluconazole
Description: Multiple oral doses
Study NCT01772290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: Multiple oral doses
Study NCT01772290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: Multiple oral doses
Study NCT01772290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vismodegib
Description: Multiple oral doses
Study NCT01772290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vismodegib
Description: Multiple oral doses
Study NCT04492228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Eucaloric Ketogenic diet % composition : protein (27%), lipids (67%), carbohydrates (6%: \<30g/day). In pts in artificial nutrition : Eucaloric Ketogenic parenteral nutrition % composition : aminoacids (27%), lipids (67%), carbohydrates (6%: \<30g/day)
Study NCT02589730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Welltang App
Description: This App is a large platform of individualized diabetic management
Study NCT00073346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment
Study NCT02371434 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous CD4+CD25+FoxP3+ natural regulat. T cells (nTregs)
Description: autologous CD4+CD25+FoxP3+ natural regulatory T cells (nTregs). nTregs will be infused at escalating doses of 0.5 x 10\^6, 1 x 10\^6, and 2.5-3 x 10\^6 cells/kg body weight in cohorts of three patients each.
Study NCT02377297 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restoration with Fuji IX
Description: The cavities will be restored with Fuji IX (GC Europe, Leuven, BE).
Study NCT02377297 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restoration with Vitro Molar
Description: The cavities will be restored with Vitro Molar (DHL, Rio de Janeiro, BR).
Study NCT02377297 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restoration with Maxxion R
Description: The cavities will be restored with Maxxion R (FGM, Rio de Janeiro, BR).
Study NCT00580450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1
Description: 1.6 mg sc once a day for 16 weeks
Study NCT00786214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Patients will be stimulated at specific acupuncture points as determined for treatment of the disease by certified acupuncturists
Study NCT00786214 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Patients will be given sham acupuncture treatment at dummy acupuncture points
Study NCT02404805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolutegravir
Description: dolutegravir tablets 50mg, once daily x 7 days.
Study NCT02404805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simeprevir
Description: simeprevir tablets 150mg, once daily x 7 days.
Study NCT05973799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Subjects remain fasted prior to insulin-induced hypoglycemia.
Study NCT05973799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feeding
Description: Subjects eat a normal breakfast and lunch prior to insulin-induced hypoglycemia.
Study NCT01175980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04623892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2618 injection
Description: TQB2618 administered intravenously (IV) on Day 1 of each 21-day. The established dose of TQB2618 is diluted to 100 m with normal saline \[0.9% (w/v) sodium chloride solution\], and the infusion time is 60 ± 10 min.
Study NCT00573261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Subjects will take pregabalin for the duration of four weeks. The dosage will range from 75 mg twice a day to 300 mg twice a day.
Study NCT00573261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take placebo for the duration of four weeks. The dosage will range from 75 mg twice a day to 300 mg twice a day.
Study NCT04766645 — intervention group
Intervention type: DEVICE
Intervention: Robotic assisted intervention
Description: Conventional rehabilitation and Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
Study NCT04766645 — intervention group
Intervention type: GENETIC
Intervention: epigenetic analyses
Description: Epigenetic study: evaluation of methylation levels of ACE2 promoter and miR-200c-3p levels.
Study NCT04766645 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: biochemical analyses
Description: Biochemical analysis: the evaluation of serum levels of angiotensin II, ACE2 and Vitamin D.
Study NCT03304301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sunlight exposure
Description: Participants will be encouraged to reduce time spent on bed and bedroom. We will also take participants outdoors and receiving sunlight exposure (if the UV index is over 8 according to the forecast of Center Weather Bureau, the participants will be asked to stay inside) five days a week for three months
Study NCT03397225 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention
Description: The educational sessions and individual sessions including dietary management and physical activity advices.
Study NCT03397225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: The educational sessions and individual sessions including dietary management and physical activity advices.
Study NCT03213444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant chemotherapy with 5-FU isolated
Description: Patients submitted to adjuvant chemotherapy with 5-FU isolated
Study NCT03213444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant chemotherapy with 5-FU associated with oxaliplatin
Description: Patients submitted to adjuvant chemotherapy with 5-FU associated with oxaliplatin
Study NCT00764621 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracellular contrast media (ECCM) MRI
Description: Contrast-enhanced MRI with an i.v. application of an approved extracellular contrast medium in the approved dosage
Study NCT00764621 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Contrast-enhanced CT
Description: Contrast-enhanced 3 phase multidetector CT with an i.v. application of an approved iodinated contrast medium in the approved dosage
Study NCT00963573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
Study NCT00963573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone
Description: loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
Study NCT03757858 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermotron RF-8
Description: Hyperthermia for 40 minutes, with maximum temperature setted on 42℃ ± 0.5℃ as upper limit, twice a week for a total of 10 times.
Study NCT03757858 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermotron RF-8
Description: Hyperthermia for 40 minutes, with maximum temperature setted on 42℃ ± 0.5℃ as upper limit, twice a week for a total of 10 times.
Study NCT03757858 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adoptive cellular Immunotherapy
Description: Mononuclear cells were collected from 50ml peripheral blood , and cultured cytokine-induced killer cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of CIK Immunotherapy . If the evaluation of the treatment is complete response, partial response or stable disease, additional cycles were eligible.
Study NCT04512248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quit and Stay Quit Monday Model
Description: Participants randomized to the study intervention will receive: (1) 2 telephone smoking cessation coaching calls; (2) enrollment into SmokefreeTXT; and (3) enrollment in the iquitmonday.org weekly email newsletter. The telephone coaches will ask these participants to identify a future Monday as their quit date and provide coaching to achieve a Monday quit. The coaches will also enter the selected Monday as the patient's quit day when enrolling the patient into SmokefreeTXT.
Study NCT03757858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 antibody
Description: Patients will receive pembrolizumab 100mg every three weeks and assess the clinical outcome every 2 dosage of anti-PD-1 antibody treatment.
Study NCT03757858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Patients will receive standard chemotherapy until disease progression, unacceptable toxicity or patient refusal.
Study NCT03757858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Patients will receive standard chemotherapy until disease progression, unacceptable toxicity or patient refusal.
Study NCT04190121 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: prosure
Description: The study group will receive the dietary supplement preoperatively and for three months after the operation
Study NCT01674218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin will be given orally to the following treatment groups, in combination with either PA-824 or PA-824 placebo: Treatment D: 400 mg + PA-824 placebo; Treatment E: 400 mg + PA-824 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
Study NCT01674218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin will be given orally to the following treatment groups, in combination with either PA-824 or PA-824 placebo: Treatment D: 400 mg + PA-824 placebo; Treatment E: 400 mg + PA-824 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
Study NCT01674218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: PA-824 will be given orally to the following treatment groups, together with either moxifloxacin or moxifloxacin placebo: Treatment B: 400 mg + moxifloxacin placebo; Treatment C: 1000 mg + moxifloxacin placebo; Treatment E: 400 mg + moxifloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
Study NCT01175980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study NCT01674218 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets to match Moxifloxacin or PA-824 will be given orally, in combination with either moxifloxacin or PA-824: Treatment A: PA-824 placebo + moxifloxacin placebo; Treatment B: PA-824 400 mg + moxifloxacin placebo; Treatment C: PA-824 1000 mg + moxifloxacin placebo Treatment D: PA-824 placebo + moxafloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
Study NCT01674218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets to match Moxifloxacin or PA-824 will be given orally, in combination with either moxifloxacin or PA-824: Treatment A: PA-824 placebo + moxifloxacin placebo; Treatment B: PA-824 400 mg + moxifloxacin placebo; Treatment C: PA-824 1000 mg + moxifloxacin placebo Treatment D: PA-824 placebo + moxafloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.